Christopher Ryan Cave Barrett - 11 Sep 2026 Form 4 Insider Report for AtaiBeckley Inc. (ATAI)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
11 Sep 2026, 17:44:28 UTC
Prior SEC filing
03 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ryan Barrett

Key filing fact

Christopher Ryan Cave Barrett filed Form 4 for AtaiBeckley Inc. (ATAI) on 11 Sep 2026.

Key facts

  • This page summarizes Christopher Ryan Cave Barrett's Form 4 filing for AtaiBeckley Inc. (ATAI).
  • 11 reported transactions and 10 derivative rows are listed below.
  • Accepted by SEC: 11 Sep 2026, 17:44.

Change

  • Previous filing in this sequence was filed on 03 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002087548 Primary reporting owner

Barrett Christopher Ryan Cave

Relationship
Chief Legal and Business Officer
Address
C/O ATAI LIFE SCIENCES US, INC., C/O INDUSTRIOUS NYC, 250 WEST 34TH ST., NEW YORK
Signature
/s/ Ryan Barrett
Signature date
11 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATAI transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-155,066
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-347,000
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
347,000
Exercise price
$2.44
Footnotes
F3
ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-284,832
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
284,832
Exercise price
$5.68
Footnotes
F3
ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-231,900
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
231,900
Exercise price
$5.54
Footnotes
F3
ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-71,620
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
71,620
Exercise price
$2.86
Footnotes
F3
ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-400,000
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
400,000
Exercise price
$1.18
Footnotes
F3
ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-550,000
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
550,000
Exercise price
$1.84
Footnotes
F3
ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-757,915
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
757,915
Exercise price
$1.50
Footnotes
F3
ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-175,000
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
175,000
Exercise price
$5.20
Footnotes
F3
ATAI transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-675,000
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
675,000
Exercise price
$3.76
Footnotes
F3
ATAI transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-150,000
Change %
-100%
Price
Shares after
0
Date
11 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
150,000
Exercise price
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Christopher Ryan Cave Barrett is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

Footnote F2

At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.

Footnote F3

At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Footnote F4

At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting).

SEC remarks

Chief Legal and Business Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .